Close Menu

NEW YORK – Epigenetics diagnostics firm VolitionRx today priced its public offering of 4,365,000 shares of common stock at $2.75 per share.

The firm said it expects to receive gross proceeds, excluding the exercise of the over-allotment option, of $12 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.